Pharmacotherapy for obesity management
RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade...
Gespeichert in:
| Veröffentlicht in: | South African medical journal Jg. 115; H. 10b; S. e3767 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
South African Medical Association
04.11.2025
|
| Schlagworte: | |
| ISSN: | 0256-9574, 2078-5135 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade A] liraglutide 3.0 mg daily [Level 2a, grade B], naltrexone/bupropion 16 mg/180 mg twice a day [BID] [Level 2a, Grade B], orlistat 120 mg three times a day [TID] [Level 2a, Grade B]). 2. Pharmacotherapy may be used to maintain weight loss and to prevent weight regain (liraglutide 3.0 mg daily [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 3. Pharmacotherapy for obesity management in conjunction with health behaviour changes for people living with prediabetes and overweight or obesity (BMI ≥27 kg/m2) can be used to delay or prevent T2DM (liraglutide 3.0 mg daily [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 4. Obesity pharmacotherapy can be used in conjunction with health behaviour changes in people living with T2DM and a BMI ≥27 kg/m2, for weight loss and improvement in glycaemic control (semaglutide 2.4 mg weekly [Level 1a, Grade A], liraglutide 3.0 mg daily [Level 1b, Grade A], naltrexone/bupropion 16 mg/180 mg BID [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 5. Pharmacotherapy can be considered in conjunction with health behaviour changes in treating people with obstructive sleep apnoea and a BMI ≥30 kg/m2, for weight loss and associated improvement in the apnoea-hypopnoea index (liraglutide 3.0 mg daily [Level 2a, Grade B]). 6. Pharmacotherapy can be considered in conjunction with health behaviour changes in treating people living with metabolic dysfunction- associated steatohepatitis (MASH) and overweight or obesity, for weight loss and improvement of MASH parameters (liraglutide 1.8 mg daily [Level 3; Grade C], semaglutide 2.4 mg [Level 4 Grade D]). 7. Metformin and psychological treatment (such as cognitive behavioural therapy) should be considered for prevention of weight gain in people with severe mental illness who are treated with antipsychotic medications associated with weight gain (Level 1a, Grade A). 8. For people living with overweight or obesity who require pharmacotherapy for other health conditions, we suggest choosing medications that are not associated with weight gain (Level 4, Grade D, Consensus). 9. We do not suggest the use of prescription or over-the-counter medications other than those approved in SA for obesity management (Level 4, Grade D, Consensus). |
|---|---|
| AbstractList | RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade A] liraglutide 3.0 mg daily [Level 2a, grade B], naltrexone/bupropion 16 mg/180 mg twice a day [BID] [Level 2a, Grade B], orlistat 120 mg three times a day [TID] [Level 2a, Grade B]). 2. Pharmacotherapy may be used to maintain weight loss and to prevent weight regain (liraglutide 3.0 mg daily [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 3. Pharmacotherapy for obesity management in conjunction with health behaviour changes for people living with prediabetes and overweight or obesity (BMI ≥27 kg/m2) can be used to delay or prevent T2DM (liraglutide 3.0 mg daily [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 4. Obesity pharmacotherapy can be used in conjunction with health behaviour changes in people living with T2DM and a BMI ≥27 kg/m2, for weight loss and improvement in glycaemic control (semaglutide 2.4 mg weekly [Level 1a, Grade A], liraglutide 3.0 mg daily [Level 1b, Grade A], naltrexone/bupropion 16 mg/180 mg BID [Level 2a, Grade B], orlistat 120 mg TID [Level 2a, Grade B]). 5. Pharmacotherapy can be considered in conjunction with health behaviour changes in treating people with obstructive sleep apnoea and a BMI ≥30 kg/m2, for weight loss and associated improvement in the apnoea-hypopnoea index (liraglutide 3.0 mg daily [Level 2a, Grade B]). 6. Pharmacotherapy can be considered in conjunction with health behaviour changes in treating people living with metabolic dysfunction- associated steatohepatitis (MASH) and overweight or obesity, for weight loss and improvement of MASH parameters (liraglutide 1.8 mg daily [Level 3; Grade C], semaglutide 2.4 mg [Level 4 Grade D]). 7. Metformin and psychological treatment (such as cognitive behavioural therapy) should be considered for prevention of weight gain in people with severe mental illness who are treated with antipsychotic medications associated with weight gain (Level 1a, Grade A). 8. For people living with overweight or obesity who require pharmacotherapy for other health conditions, we suggest choosing medications that are not associated with weight gain (Level 4, Grade D, Consensus). 9. We do not suggest the use of prescription or over-the-counter medications other than those approved in SA for obesity management (Level 4, Grade D, Consensus). |
| Author | Hellig, J Noeth, M May, W Van Zyl, F H Conradie-Smit, M |
| Author_xml | – sequence: 1 givenname: M orcidid: 0000-0002-0563-5617 surname: Noeth fullname: Noeth, M – sequence: 2 givenname: F H orcidid: 0009-0005-5540-973X surname: Van Zyl fullname: Van Zyl, F H – sequence: 3 givenname: J orcidid: 0009-0001-2747-5415 surname: Hellig fullname: Hellig, J – sequence: 4 givenname: M surname: Conradie-Smit fullname: Conradie-Smit, M – sequence: 5 givenname: W orcidid: 0009-0004-8573-224X surname: May fullname: May, W |
| BookMark | eNo9kF1LwzAUhoNMcJv-BdmVd61J2iTN5Rh-TCYK6nU4SU62jrUZaRH27211eHV4zwsPL8-MTNrYIiG3jOaKaXn_sXx9yTnlIv9mTNTa5oWS6oJMOVVVJlghJmQ61DLTQpVXZNZ1ezpkoeWU3L3vIDXgYr_DBMfTIsS0iBa7uj8tGmhhiw22_TW5DHDo8OZ85-Tr8eFz9Zxt3p7Wq-Umc0wylUkWaCWYcBi8YgVXWivPKmQloHeqslRya3UpnAUOilpaCk8FFUEK0BqLOVn_cX2EvTmmuoF0MhFq8_uIaWsg9bU7oOHUM89txQuBZeBgKQbNrR8nFAN6YMk_lkux6xKGfx6jZjRnRnNmNGfO5sxorvgBO_hjsA |
| ContentType | Journal Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.7196/SAMJ.2025.v115i9b.3767 |
| DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2078-5135 |
| ExternalDocumentID | oai_doaj_org_article_20d1d2b8235e4f2ab0ef92bd1f08370b 10_7196_SAMJ_2025_v115i9b_3767 |
| GroupedDBID | --- -OY 123 1RG 4JU 53G 5RE 5VS 6SC AAFWJ AAWTL AAYXX ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS ANHLU APOWU AZFZN BAWUL BCNDV CITATION DIK EBD EBS EJD EMOBN F5P FRP GROUPED_DOAJ GX1 IAO IHR IHW INH INR ITC JRA KWQ L7B MK0 OK1 P2P RFP RNS SCVUT SV3 SWNBY TR2 W2D |
| ID | FETCH-LOGICAL-c1617-61f08515cefd71327997d18e14aedc78b062bb945cba2a70b045d0505f65a99e3 |
| IEDL.DBID | DOA |
| ISSN | 0256-9574 |
| IngestDate | Mon Nov 10 19:21:46 EST 2025 Wed Nov 05 20:50:55 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10b |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1617-61f08515cefd71327997d18e14aedc78b062bb945cba2a70b045d0505f65a99e3 |
| ORCID | 0009-0001-2747-5415 0009-0005-5540-973X 0000-0002-0563-5617 0009-0004-8573-224X |
| OpenAccessLink | https://doaj.org/article/20d1d2b8235e4f2ab0ef92bd1f08370b |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_20d1d2b8235e4f2ab0ef92bd1f08370b crossref_primary_10_7196_SAMJ_2025_v115i9b_3767 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-11-04 |
| PublicationDateYYYYMMDD | 2025-11-04 |
| PublicationDate_xml | – month: 11 year: 2025 text: 2025-11-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationTitle | South African medical journal |
| PublicationYear | 2025 |
| Publisher | South African Medical Association |
| Publisher_xml | – name: South African Medical Association |
| SSID | ssj0025596 ssib045324610 ssib022775494 ssib005229541 |
| Score | 2.4019754 |
| Snippet | RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications,... |
| SourceID | doaj crossref |
| SourceType | Open Website Index Database |
| StartPage | e3767 |
| SubjectTerms | Guideline Medication Obesity Pharmacotherapy South Africa |
| Title | Pharmacotherapy for obesity management |
| URI | https://doaj.org/article/20d1d2b8235e4f2ab0ef92bd1f08370b |
| Volume | 115 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2078-5135 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025596 issn: 0256-9574 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NSwMxEA1SRLyIn1i_2IN423Y3m2ySYxWLCC0FFXoLySaBHmylrQX_vTPZta0nL16XZdl5GTLvkcwbQm6BA6BLl0ptCCyFDa9MJRUupYEZmXPnuJFx2IQYDuV4rEZbo77wTlhtD1wDB-Lc5Y5aSQvuWaDGZj4oal0eMvRtsbj7ZkJtiamYWTilelPoKUWjt03mMV6gj1q2lmbAq-OpJhCAVHHB6l5iAenZfekNnkFHUt5ZAXuaKNtBA5RfZWzL7T-Wpf4hOWj4ZNKr4zgiO356TPYGzYn5CbkbNd7UdaPVVwIkNZnV0wCS9_Xdl1Py1n98fXhKm9kIaYWKBBRfQLLEKx8c6EwqlBIulz5nxrtKSJuV1FrFeGUNNYATxOxwal0ouVHKF2ekNZ1N_TlJQMI4x3IbnIx9tcorx4MPRW5EsL5sk-5PqPqjtsDQIB0QHI3gaARHN-BoBKdN7hGR9dtoYR0fwMLqZmH1Xwt78R8fuST7-HexeZBdkdZy_umvyW61Wk4W85uYM9_eXb0E |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacotherapy+for+obesity+management&rft.jtitle=South+African+medical+journal&rft.au=M+Noeth&rft.au=F+H+Van+Zyl&rft.au=J+Hellig&rft.au=M+Conradie-Smit&rft.date=2025-11-04&rft.pub=South+African+Medical+Association&rft.issn=0256-9574&rft.eissn=2078-5135&rft.volume=115&rft.issue=10b&rft_id=info:doi/10.7196%2FSAMJ.2025.v115i9b.3767&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_20d1d2b8235e4f2ab0ef92bd1f08370b |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0256-9574&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0256-9574&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0256-9574&client=summon |